PMID- 26421711 OWN - NLM STAT- MEDLINE DCOM- 20160815 LR - 20181202 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 6 IP - 31 DP - 2015 Oct 13 TI - Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. PG - 30453-71 LID - 10.18632/oncotarget.5852 [doi] AB - Here, we developed an isogenic cell model of "stemness" to facilitate protein biomarker discovery in breast cancer. For this purpose, we used knowledge gained previously from the study of the mouse mammary tumor virus (MMTV). MMTV initiates mammary tumorigenesis in mice by promoter insertion adjacent to two main integration sites, namely Int-1 (Wnt1) and Int-2 (Fgf3), which ultimately activates Wnt/beta-catenin signaling, driving the propagation of mammary cancer stem cells (CSCs). Thus, to develop a humanized model of MMTV signaling, we over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. We then validated that MCF7 cells over-expressing both WNT1 and FGF3 show a 3.5-fold increase in mammosphere formation, and that conditioned media from these cells is also sufficient to promote stem cell activity in untransfected parental MCF7 and T47D cells, as WNT1 and FGF3 are secreted factors. Proteomic analysis of this model system revealed the induction of i) EMT markers, ii) mitochondrial proteins, iii) glycolytic enzymes and iv) protein synthesis machinery, consistent with an anabolic CSC phenotype. MitoTracker staining validated the expected WNT1/FGF3-induced increase in mitochondrial mass and activity, which presumably reflects increased mitochondrial biogenesis. Importantly, many of the proteins that were up-regulated by WNT/FGF-signaling in MCF7 cells, were also transcriptionally over-expressed in human breast cancer cells in vivo, based on the bioinformatic analysis of public gene expression datasets of laser-captured patient samples. As such, this isogenic cell model should accelerate the discovery of new biomarkers to predict clinical outcome in breast cancer, facilitating the development of personalized medicine.Finally, we used mitochondrial mass as a surrogate marker for increased mitochondrial biogenesis in untransfected MCF7 cells. As predicted, metabolic fractionation of parental MCF7 cells, via MitoTracker staining, indicated that high mitochondrial mass is a new metabolic biomarker for the enrichment of anabolic CSCs, as functionally assessed by mammosphere-forming activity. This observation has broad implications for understanding the role of mitochondrial biogenesis in the propagation of stem-like cancer cells. Technically, this general metabolic approach could be applied to any cancer type, to identify and target the mitochondrial-rich CSC population.The implications of our work for understanding the role of mitochondrial metabolism in viral oncogenesis driven by random promoter insertions are also discussed, in the context of MMTV and ALV infections. FAU - Lamb, Rebecca AU - Lamb R AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Bonuccelli, Gloria AU - Bonuccelli G AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Ozsvari, Bela AU - Ozsvari B AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Peiris-Pages, Maria AU - Peiris-Pages M AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Fiorillo, Marco AU - Fiorillo M AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Department of Pharmacy, Health and Nutritional Sciences, The University of Calabria, Cosenza, Italy. FAU - Smith, Duncan L AU - Smith DL AD - The Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK. FAU - Bevilacqua, Generoso AU - Bevilacqua G AD - FPS - The Pisa Science Foundation, Pisa, Italy. AD - Department of Pathology, Pisa University Hospital, Pisa, Italy. FAU - Mazzanti, Chiara Maria AU - Mazzanti CM AD - FPS - The Pisa Science Foundation, Pisa, Italy. FAU - McDonnell, Liam A AU - McDonnell LA AD - FPS - The Pisa Science Foundation, Pisa, Italy. FAU - Naccarato, Antonio Giuseppe AU - Naccarato AG AD - Department of Pathology, Pisa University Hospital, Pisa, Italy. FAU - Chiu, Maybo AU - Chiu M AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Wynne, Luke AU - Wynne L AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Martinez-Outschoorn, Ubaldo E AU - Martinez-Outschoorn UE AD - The Sidney Kimmel Cancer Center, Philadelphia, PA, USA. FAU - Sotgia, Federica AU - Sotgia F AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. FAU - Lisanti, Michael P AU - Lisanti MP AD - The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK. AD - The Manchester Centre for Cellular Metabolism (MCCM), Institute of Cancer Sciences, University of Manchester, Manchester, UK. LA - eng GR - K08 CA175193/CA/NCI NIH HHS/United States GR - K08-CA175193-01A1/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Biomarkers, Tumor) RN - 0 (Culture Media, Conditioned) RN - 0 (FGF3 protein, human) RN - 0 (Fibroblast Growth Factor 3) RN - 0 (WNT1 protein, human) RN - 0 (Wnt1 Protein) SB - IM CIN - Oncotarget. 2015 Nov 17;6(36):38442-3. PMID: 26564961 MH - Biomarkers, Tumor/*physiology MH - Breast Neoplasms/*pathology MH - Culture Media, Conditioned/pharmacology MH - Female MH - Fibroblast Growth Factor 3/*biosynthesis/metabolism MH - Humans MH - MCF-7 Cells MH - Mammary Tumor Virus, Mouse/genetics/pathogenicity MH - Membrane Potential, Mitochondrial/physiology MH - Mitochondria/metabolism/*physiology MH - Models, Biological MH - Neoplastic Stem Cells/cytology/pathology MH - Spheroids, Cellular/cytology MH - Tumor Cells, Cultured MH - Wnt Signaling Pathway/physiology MH - Wnt1 Protein/*biosynthesis/metabolism PMC - PMC4741544 OTO - NOTNLM OT - FGF OT - MMTV OT - MitoTracker OT - WNT OT - mitochondria COIS- CONFLICTS OF INTEREST There is no conflict of interest. EDAT- 2015/10/01 06:00 MHDA- 2016/08/16 06:00 PMCR- 2015/10/13 CRDT- 2015/10/01 06:00 PHST- 2015/07/21 00:00 [received] PHST- 2015/08/22 00:00 [accepted] PHST- 2015/10/01 06:00 [entrez] PHST- 2015/10/01 06:00 [pubmed] PHST- 2016/08/16 06:00 [medline] PHST- 2015/10/13 00:00 [pmc-release] AID - 5852 [pii] AID - 10.18632/oncotarget.5852 [doi] PST - ppublish SO - Oncotarget. 2015 Oct 13;6(31):30453-71. doi: 10.18632/oncotarget.5852.